Keywords
Preventive dentistry
Antiresorptive drugs
Neoplastic metastasis
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To evaluate the extent of medical referral of oncology patients undergoing treatment with antiresorptive drugs for prior and ongoing dental follow-up, with the aim of preventing medication-related osteonecrosis of the jaws (MRONJ), as well as to assess whether these patients were adequately informed about the potential side effects and associated risk factors of the medication. Methods: This cross-sectional, quantitative study was conducted at the reference hospital for cancer treatmentwith a sample of 70 patients receiving zoledronic acid (Zometa®). Data were collected through structured interviews using a multiple-choice questionnaire. Responses were entered into the Google Forms platform to calculate percentage distributions. Results: The majority of participants (85.5%) were not referred for a dental consultation prior to initiating treatment with zoledronic acid. Additionally, 22.8% were referred during the course of treatment, and 72.1% reported receiving no information regarding potential side effects. Conclusion: The findings underscore the need to strengthen collaboration between medical and dental care teams and to enhance patient education regarding preventive measures and the adverse effects associated with antiresorptive therapy.
References
ALDHALAAN NA, et al. Medication-related osteonecrosis of the jaw: a review. Cureus, 2020; 12(2): e6944.
AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS (AAOMS). Position paper on bisphosphonate-related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery, 2007; 65(3): 369–376.
BOZYEL B, et al. Hypoxic responses in periodontal tissues: influence of smoking and periodontitis. Journal of Clinical Periodontology, 2025; 52(2): 249–257.
CAMPISI G, et al. Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020. International Journal of Environmental Research and Public Health, 2020; 17(16): e5922.
CHEN F, et al. Bone marrow niches in the regulation of bone metastasis. Frontiers in Oncology, 2021; 124(12): 1912–1920.
DEAN D, et al. Dental evaluation and clearance prior to allogeneic hematopoietic cell transplantation. Oral Diseases, 2024; 30(4): 2635–2644.
DILLEKAS H, et al. Are 90% of deaths from cancer caused by metastases? Cancer Medicine, 2019; 8(12): 5574–5576.
D'ORONZO S, et al. Metastatic bone disease: pathogenesis and therapeutic options: update on bone metastasis management. Journal of Bone Oncology, 2018; 15: 100232.
HUANG JF, et al. Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Annals of Translational Medicine, 2020; 8(7): e435.
HONG S, et al. Bone metastasis and skeletal-related events in patients with solid cancer: a Korean Nationwide Health Insurance Database Study. PLoS ONE, 2020; 15(7): e0236025.
JENSEN PR, et al. Bisphosphonates impair the onset of bone formation at remodeling sites. Bone, 2021; 142: 115715.
KIM HW, et al. Comparison of the effect of oral versus intravenous bisphosphonates on RANKL/OPG ratio in jawbones: implications for MRONJ. Journal of Clinical Medicine, 2021; 10(13): e2904.
LEE ES, et al. Bisphosphonates and their connection to dental procedures: exploring bisphosphonate-related osteonecrosis of the jaws. Cancers, 2023; 15(22): e5369.
LORENZO-POUSO AI, et al. Biomarkers to predict the onset of bisphosphonate-related osteonecrosis of the jaw: a systematic review. Medicina Oral, Patología Oral y Cirugía Bucal, 2019; 24(1): 26–36.
MACIEL GBM, et al. O papel da infecção e inflamação na etiopatogênese da osteonecrose dos maxilares induzida por medicamentos. Revista da Faculdade de Odontologia da UPF, 2023; 28(1): e481.
MADEIRA M, et al. Prevention and treatment of oral adverse effects of antiresorptive medications for osteoporosis: a position paper. Archives of Endocrinology and Metabolism, 2020; 64: 664–672.
MARX RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery, 2003; 61(9): 1115–1117.
MCDONALD D, et al. Treatment of hypercalcaemia of malignancy in adults. Clinical Medicine (Londres), 2023; 23(5): 503–507.
McGOWAN K, et al. Both non-surgical dental treatment and extractions increase the risk of medication-related osteonecrosis of the jaw: case-control study. Clinical Oral Investigations, 2019; 23: 3967–3975.
MOURA AM, et al. Osteorradionecrose em maxila e mandíbula decorrente de tratamento radioterápico. Brazilian Journal of Health Review, 2022; 5(1): 2052–2060.
NOWICKI B, et al. Medication-related osteonecrosis of the jaw in a minipig model: parameters for developing a macroscopic, radiological and microscopic grading scheme. Journal of Craniomaxillofacial Surgery, 2019; 47(7): 1162–1169.
NICOLATOU-GALITIS O, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2019; 127(2): 117–135.
PAUL J, et al. Smoking and its effects on periodontium – a review. Journal of Pierre Fauchard Academy (India Section), 2022; 36(3): 81–90.
RÁZAVI V, et al. Efficacy of adjunctive photobiomodulation management of medication-related osteonecrosis of the jaw: a systematic review. Photomedicine and Laser Surgery, 2022; 40(12): 777–791.
RUGGIERO SL, et al. Practical guidelines for prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice, 2006; 2(1): 7–14.
RUGGIERO SL, et al. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws — 2022 Update. Journal of Oral and Maxillofacial Surgery, 2022; 80(5): 920–943.
SAINT-ANDRÉ V, et al. Smoking changes adaptive immunity with persistent effects. Nature, 2024; 615(7951): 125–133.
SEVİNC A. Bisphosphonate osteonecrosis in clinical practice: a scoping review with special emphasis on pamidronate therapy. Clinics in Oncology, 2024; 9(2112): e2112.
SHARMA P, et al. The impact of smoking on periodontal health: a comprehensive review. Journal of Oral Biology and Craniofacial Research, 2024; 14(1): 1–10.
SILVA TSG, et al. Avaliação odontológica prévia ao uso de drogas antirreabsortivas para prevenção da osteonecrose dos maxilares em pacientes com osteoporose. Revista Eletrônica Acervo Saúde, 2024; 24(10): e12048.
SUBRAMANIAN RC, et al. Review of bone modifying agents in metastatic breast cancer. Cureus, 2021; 13(2): e13214.
SURYANI IR, et al. Non-antiresorptive drugs associated with the development of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. Clinical Oral Investigations, 2022; 26(3): 2269–2279.
TAMMA R, et al. The role of bone stem cell niches in bone metastasis. Applied Sciences, 2020; 10(21): e7534.
TANIOS M, et al. Diabetes and impaired fracture healing: a narrative review of recent literature. Current Osteoporosis Reports, 2022; 20: 229–239.
THOMAS JG, OUANOUNOU A. Medication-related osteonecrosis of the jaw: a narrative review of risk factors, diagnosis, and management. Frontiers of Oral and Maxillofacial Medicine, 2023; 5: 31